SIGA Technologies (SIGA) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed SIGA Technologies (SIGA) over the past year, gaining 53.0% versus a loss of 60.4%. Over five years, SIGA leads with a -53.9% price change compared with -96.6% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $235.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SIGA | ZNTL |
|---|---|---|
| Share price | $3.28 | $2.64 |
| Market cap | $235.67M | $259.04M |
| 1-day change | 0.00% | +5.18% |
| YTD return | -46.32% | +85.93% |
| 1-year return | -60.39% | +53.05% |
| 5-year return | -53.87% | -96.65% |
| Forward P/E | 3.04 | — |
| EPS (TTM) | $-0.04 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.55 | $6.95 |
| 52-week low | $2.83 | $1.21 |
| Distance from 52-week high | -61.64% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | — | +177.65% |
| Average volume | 726.75K | 1.21M |
| Shares outstanding | 71.85M | 98.12M |
| Employees | 49 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed SIGA by 113.4 percentage points over the past year.
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
SIGA vs ZNTL FAQ
Which is bigger, SIGA Technologies or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $235.67M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, SIGA or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with -60.39% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are SIGA Technologies and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.